Charitable Gift Activity Nearing Pre-Pandemic Levels According to BNY Mellon Wealth Management 2022 Annual Charitable Gift Report
Charitable Gift Activity Nearing Pre-Pandemic Levels According to BNY Mellon Wealth Management 2022 Annual Charitable Gift Report
PR Newswire
NEW YORK, Aug. 17, 2022
NEW YORK, Aug. 17, 2022 /PRNewswire/ — BNY Mellon Wealth Management today release…

Charitable Gift Activity Nearing Pre-Pandemic Levels According to BNY Mellon Wealth Management 2022 Annual Charitable Gift Report
PR Newswire
NEW YORK, Aug. 17, 2022
NEW YORK, Aug. 17, 2022 /PRNewswire/ -- BNY Mellon Wealth Management today released its 2022 Annual Charitable Gift Report, which found that charitable giving started to rebound in 2021 after declining in 2020, with the number and total dollar amount of gifts increasing (10%), and the average gift size also increasing (27%).
Positive Progress in 2021
Charitable gift activity overall returned to historical, pre-pandemic trends as many nonprofits found ways to pivot and discover new approaches to build support for their missions and connect with donors.
"The financial markets held strong in 2021 and the planned giving activity demonstrated how sustainable the giving increase in 2020 was – and even with the present market uncertainty, people don't stop giving," said Crystal Thompkins, head of philanthropic solutions at BNY Mellon Wealth Management. "With the majority of planned gifts still being funded with cash, it's important to focus on conversations about appreciated assets and ownership. There are significant opportunities for nonprofits to optimize giving by working with donors to consider non-cash gifts and craft unique gift solutions."
- Gift by Size: Gifts of more than $100,000 represented 29% of the total contracts in 2021 but accounted for 85% of the total gift dollars. Gifts between $10,000 and $50,000 represented most contracts at 54%, the same as in 2020.
- Cash Gifts vs. Non-Cash Gifts: Cash gifts are still by far the most popular (83%), with non-cash gifts representing 17%, nearly identical to year over year comparisons.
- Gift Flows: The gift flow ratio was 1.09, indicating new gift activity outplaced gift terminations. This was driven by healthcare organizations that experienced an increase in gift flows from .68 in 2020 to 2.24 in 2021. Faith-based/religious organizations experienced the biggest drop, decreasing from 2.94 in 2020 to .93 in 2021.
- New Trust Activity: There was a 33% increase in new trust activity year over year, though total gift amounts decreased and the dollar amount of additions to trusts decreased by 50%.
Thompkins commented, "Although there was a slight uptick in the number of new trusts in 2021, trust activity continues its relatively flat to downward trend since the 2008-09 recession driven by lower charitable deductions due to the low applicable fed rate (AFR) and donors looking to make a more immediate impact with their giving. That said, trusts are still a giving strategy that can provide solutions to both tax and estate planning needs and philanthropic goals, especially as part of a comprehensive giving strategy."
New Donors Outnumber Repeat Donors
When donors have access to the right information and advice, they are able to explore more charitable options to achieve their philanthropic goals. While attorneys and CPAs play an important role with donors in terms of gift execution, wealth advisors provide significant guidance when it comes to donors' philanthropy.
- New Versus Repeat Donors: New donors (51%) outnumbered repeat donors (49%) and made larger gifts on average (18.5% increase in average gift size).
Donor Advised Funds Remain a Bulletproof Strategy, According to BNY Mellon Wealth Management's Client Activity
Donor advised funds (DAFs) continue to be an important part of the philanthropic landscape, and often are considered as the preferred option for charitable giving. According to the report, grants distributed through the BNY Mellon Charitable Gift Fund experienced a record-level gift activity in 2021, with an increase in gift count of 93%, and gift amount of 55%.
"During times of economic uncertainty when capacity for charitable giving may be limited, donors with DAFs are well positioned to provide critical funding to nonprofits when it's needed the most," says Thompkins. "DAFs are being used in creative estate and tax planning strategies to promote legacy, family and next generation giving, which historically have been factors in forming private foundations."
The full 2022 Annual Charitable Gift Report, which includes additional findings from BNY Mellon Wealth Management's Charitable Giving Study and supporting data around BNY Mellon's Charitable Gift Fund's record-level gift activity, is available here.
Upcoming 2022 Annual Planned Giving Conference
Crystal Thompkins will host the upcoming Planned Giving Conference on September 14, 2022, featuring an in-depth look at the 2022 Charitable Gift Report findings. The annual conference convenes charitable gift planning professionals, individuals on boards of nonprofit organizations and advisors working with nonprofit organizations for a series of keynote presentations, panel discussions, peer roundtables and insights from industry experts.
About the 2022 Annual Charitable Gift Report
BNY Mellon Wealth Management's 2022 Charitable Gift Report assesses the philanthropic landscape, levels of giving over the past five years and donor behavior to provide insights, context, and benchmarks. This report provides analytics and observations on the charitable gift annuity (CGA) and charitable remainder trust (CRT) activity during the calendar year 2021 for 101 nonprofit organizations and the BNY Mellon Charitable Gift Fund. This includes stats related to life income or planned gifts. Organizations represented included education (56%); faith-based (20%); social services/other (14%); cultural (6%); and healthcare (4%). Data for the report is based on completed gift records in BNY Mellon's database as of March 30, 2022.
About BNY Mellon Wealth Management
For more than two centuries, BNY Mellon Wealth Management has provided services to financially successful individuals and families, their family offices and business enterprises, planned giving programs, and endowments and foundations. It has $264 billion in total client assets as of June 30, 2022, and an extensive network of offices in the U.S. and internationally. BNY Mellon Wealth Management, which delivers leading wealth advice across investments, banking, custody, and wealth and estate planning, conducts business through various operating subsidiaries of The Bank of New York Mellon Corporation. A line of business within Wealth Management, BNY Mellon Investor Solutions includes the firm's institutional multi-asset solutions business. The Investor Solutions AUM/AUA is $25.1bn as of June 30, 2022. For more information, visit www.bnymellonwealth.com or follow us on Twitter @BNYMellonWealth.
Media Contact:
Ben Tanner
212-635-8676
Ben.Tanner@bnymellon.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/charitable-gift-activity-nearing-pre-pandemic-levels-according-to-bny-mellon-wealth-management-2022-annual-charitable-gift-report-301607155.html
SOURCE BNY Mellon Wealth Management
Government
Family Of College Student Who Died From COVID-19 Vaccine Sues Biden Administration
Family Of College Student Who Died From COVID-19 Vaccine Sues Biden Administration
Authored by Zachary Stieber via The Epoch Times (emphasis…

Authored by Zachary Stieber via The Epoch Times (emphasis ours),
The family of a college student who died from heart inflammation caused by Pfizer’s COVID-19 vaccine has sued President Joe Biden’s administration, alleging officials engaged in “willful misconduct.”
U.S. Department of Defense (DOD) officials wrongly promoted COVID-19 vaccination by repeatedly claiming the available vaccines were “safe and effective,” relatives of George Watts Jr., the college student, said in the new lawsuit.
That promotion “duped millions of Americans, including Mr. Watts, into being DOD’s human subjects in its medical experiment, the largest in modern history,” the suit states.
The Public Readiness and Emergency Preparedness Act allows lawsuits against certain people if they have engaged in “willful misconduct” and if that misconduct caused death or serious injury.
COVID-19 vaccines are covered by the act due to a declaration entered during the Trump administration in 2020 after COVID-19 began circulating.
“DOD’s conduct and the harm caused as alleged within the four corners of the lawsuit speaks for itself,” Ray Flores, a lawyer representing the Watts family, told The Epoch Times via email. “I have no further comment other than to say: My only duty is to advocate for my client. If the DOD conveys a settlement offer, I will see that it’s considered.”
The suit was filed in U.S. court in Washington.
The Pentagon and the Department of Justice did not respond to requests for comment.
Watts Suddenly Died
Watts was a student at Corning Community College when the school mandated COVID-19 vaccination for in-person classes in 2021. He received one Pfizer dose on Aug. 27, 2021, and a second dose approximately three weeks later.
Watts soon began experiencing a range of symptoms, including tingling in the feet, pain in the heels, numbness in the hands and fingers, blood in his sperm and urine, and sinus pressure, according to family members and health records.
Watts went to the Robert Packer Hospital emergency room on Oct. 12, 2021, due to the symptoms. X-rays showed clear lungs and a normal heart outline.
Watts was sent home with suggestions to follow up with specialists but returned to the emergency room on Oct. 19, 2021, with worsening symptoms despite a week of the antibiotic Augmentin. He was diagnosed with sinusitis and bronchitis.
While speaking to his mother at home on Oct. 27, 2021, Watts suddenly collapsed. Emergency medical personnel rushed to the home but found him unresponsive. He was rushed to the same hospital in an ambulance. He was pronounced deceased at age 24.
According to a doctor at the hospital, citing hospital records and family members, Watts had no past medical history on file that would explain his sudden death, with no known history of substance abuse or obvious signs of substance abuse. His mother described her son as a “healthy young male.”
Dr. Robert Stoppacher, a pathologist who performed an autopsy on the body, said that the death was due to “COVID-19 vaccine-related myocarditis.” The death certificate listed no other causes. A COVID-19 test returned negative. Dr. Sanjay Verma, based in California, reviewed the documents in the Watts case and said that he believed the death was caused by the COVID-19 vaccination.
Pfizer did not respond to a request for comment.
Watts Took Vaccine Under Pressure
The community college mandate included a 35-day grace period following approval by the U.S. Food and Drug Administration (FDA) of a COVID-19 vaccine.
The Moderna, Pfizer, and Johnson & Johnson vaccines were given emergency use authorization early in the pandemic. The FDA approved the Pfizer shot on Aug. 23, 2021. It was the first COVID-19 vaccine approval. But doses of the approved version of the shot, branded Comirnaty, were not available for months after the approval.
Read more here...
International
US Sent Billions in Funding to China, Russia For Cat Experiments, Wuhan Lab Research: Ernst
US Sent Billions in Funding to China, Russia For Cat Experiments, Wuhan Lab Research: Ernst
Authored by Mark Tapscott via The Epoch Times…

Authored by Mark Tapscott via The Epoch Times (emphasis ours),
Hundreds of millions of U.S. tax dollars went to recipients in China and Russia in recent years without being properly tracked by the federal government, including a grant that enabled a state-run Russian lab to test cats on treadmills, according to Sen. Joni Ernst (R-Iowa).
Ernst and her staff investigators, working with auditors at the Government Accountability Office (GAO) and the Congressional Research Service, as well as two nonprofit Washington watchdogs—Open The Books (OTB) and the White Coat Waste Project (WCWP)—discovered dozens of other grants that weren’t counted on the federal government’s USASpending.gov internet database.
While the total value of the uncounted grants found by the Ernst team is $1.3 billion, that amount is just the tip of the iceberg, the GAO reported.
Among the newly discovered grants is $4.2 million to China’s infamous Wuhan Institute of Virology (WIV) “to conduct dangerous experiments on bat coronaviruses and transgenic mice,” according to a May 31 Ernst statement provided to The Epoch Times.
The $4.2 million exposed by Ernst is in addition to previously reported funding to the WIV for extensive gain-of-function research by Chinese scientists, much of it funded in whole or part prior to the COVID-19 pandemic by National Institutes for Health (NIH) grants channeled through the EcoHealth Alliance medical research nonprofit.
The NIH has awarded seven grants totaling more than $4.1 million to EcoHealth to study various aspects of SARS, MERS, and other coronavirus diseases.
Buying Chinese Puppy Parts
As part of another U.S.-funded grant, hearts and other organs from 425 dogs in China were purchased for medical research.
“These countryside dogs in China are part of the farmer’s household; they were mainly used for guarding. Their diet includes boiled rice, discarded raw food animal tissues, and whatever dogs can forage. These dogs were sold for food,” an NIH study uncovered by the Ernst researchers reads.
Other previously unreported grants exposed by the Ernst team include $1.6 million to Chinese companies from the federal government’s National School Lunch Program and $4.7 million for health insurance from a Russian company that was sanctioned by the United States in 2022 as a result of the invasion of Ukraine.
“It’s gravely concerning that Washington’s reckless spending has reached the point where nobody really knows where all tax dollars are going,” Ernst separately told The Epoch Times. “But I have the receipts, and I’m shining a light on this, so bureaucrats can no longer cover up their tracks, and taxpayers can know exactly what their hard-earned dollars are funding.”
The problem is that federal officials don’t rigorously track sub-awards made by initial grant recipients, according to the Iowa Republican. Such sub-awards are covered by a multitude of federal regulations that stipulate many conditions to ensure that the tax dollars are appropriately spent.
The GAO said in an April report that “limitations in sub-award data is a government-wide issue and not unique to U.S. funding to entities in China.”
“GAO is currently examining the state of federal government-wide sub-award data as part of a separate review,” the report reads.

The Eco-Health sub-awards to WIV illustrate the problem.
“Despite being required by law to make these receipts available to the public on the USAspending.gov website, EcoHealth tried to cover its tracks by intentionally not disclosing the amounts of taxpayer money being paid to WIV, which went unnoticed for years,” Ernst said in the statement.
“I was able to determine that more than $490 million of taxpayer money was paid to organizations in China [in] the last five years. That’s ten times more than GAO’s estimate! Over $870 million was paid to entities in Russia during the same period!
“Together that adds up to more than $1.3 billion paid to our adversaries. But again, these numbers still do not represent the total dollar amounts paid to institutions in China or Russia since those numbers are not tracked and the information that is being collected is incomplete.”
Adam Andrzejewski, founder and chairman of OTB, told The Epoch Times, “When following the money at the state and local level, the real corruption exists in the subcontractor payments. At the federal level, the existing system doesn’t even track many of those recipients.
“Without better reporting, agencies and appropriators don’t truly understand how tax dollars were used. We now know that taxpayer dollars are traded further downstream than originally realized with third- and fourth-tier recipients. These transactions need scrutiny. Requiring recipients to account for where and how they actually spend each dollar creates a record far better than agencies are capable of generating.”
Read more here...
Government
OraSure Technologies’ CFO Makes Bold Insider Purchase, Reigniting Investor Confidence
Executive Kenneth McGrath’s $500,000 buy read as promising signal about future for diagnostic test developer OraSure Technologies (NASDAQ:OSUR) saw…

Executive Kenneth McGrath’s $500,000 buy read as promising signal about future for diagnostic test developer
OraSure Technologies (NASDAQ:OSUR) saw a stock price re-rate on Thursday, climbing 11% after investors became aware of its CFO Kenneth McGrath buying shares in the diagnostic test developer. This latest rally in OSUR stock, gives traders and investors hope that the strong momentum from the beginning of 2023 might return.
OSUR shares had mounted an impressive 54% rally for 2023 through to May 10, when the first-quarter results update spooked investors.
The CFO’s trade was initially spotted on Fintel’s Insider Trading Tracker following the filing with the Securities and Exchange Commission.
Big Holdings Boost
In the Form 4 filing, McGrath, who assumed CFO duties in August 2022, disclosed buying 100,000 shares on May 30 in the approved trading window that was open post results.
McGrath on average paid $4.93 per share, giving the total transaction a value just shy of $500,000 and boosted his total share count ownership to 285,512 shares.
The chart below from the insider trading and analysis report for OSUR shows the share price performance and profit made from company officers in previous transactions:

Prior to joining OraSure, McGrath had an impressive eight-year tenure at Quest Diagnostics (NYSE:DGX), where he rose to the position of VP of Finance before departing. This is the first time that the CFO has bought stock in the company since August 2022. It is also worth noting that the purchase followed strong Q1 financial results, which exceeded Street forecasts.
Revenue Doubles
In its recently published Q1 update, OraSure Technologies told investors that it generated a whopping 129% increase in revenue to $155 million, surpassing analyst expectations of around $123 million.
Notably, the revenue growth was driven primarily by the success of OraSure’s COVID-19 products, which accounted for $118.4 million in revenue for the quarter and grew 282% over the previous year.
The surge in revenue for this product was largely driven by the federal government’s school testing program, which led to record test volumes. However, it is important to note that demand for InteliSwab is expected to decline in Q2 2023, prompting OraSure to scale down its COVID-19 production operations. As part of its broader strategy to consolidate manufacturing, the company plans to close an overseas production facility.
While the COVID-19 products division has been instrumental in OraSure’s recent success, its core business delivered stable flat sales of $36.6 million during the quarter.
In terms of net income, OraSure achieved an impressive result of $27.2 million, or $0.37 per share, in Q1, marking a significant improvement compared to the loss of $19.9 million, or a loss of $0.28 per share, in the same period last year. This result exceeded consensus forecasts of $0.16 per share. As of the end of the quarter, the company held $112.4 million in cash and cash equivalents.
Looking ahead to Q2, OraSure has provided revenue guidance in the range of $62 to $67 million, reflecting the lower order activity from the US government with $25 to $30 million expected sales for InteliSwab. The declining Covid related sales have been a core driver of the share price weakness in recent weeks.
While sales are likely to fall in the coming quarters, one positive for the company is its low debt balance during this period of rising cash rates. The chart below from Fintels financial metrics and ratios page for OSUR shows the cash flow performance of the business over the last five years.

Analyst Opinions
Stephen’s analyst Jacob Johnson thinks that outside of Covid, OSUR continues to execute on several cost and partnership initiatives which he believes appears to be bearing fruit. Johnson pointed out that three partnerships were signed during the quarter.
The analyst thinks that the ex-Covid growth story will be the new focus for investors from now on. The brokerage maintained its ‘equal-weight’ recommendation and $6.50 target price on the stock, matching Fintel’s consensus target price, suggesting OSUR stock could rise a further 29% in the next 12 months.
The post OraSure Technologies’ CFO Makes Bold Insider Purchase, Reigniting Investor Confidence appeared first on Fintel.
nasdaq covid-19 us government testing-
Uncategorized19 hours ago
MCT Update: Inflation Persistence Declined Significantly in April
-
International22 hours ago
Monetary Conditions Index Is Working Against The Fed
-
Government24 hours ago
CDC Data Show ‘Most Important Virus You’ve Never Heard Of’ Surged This Spring
-
Government4 hours ago
Family Of College Student Who Died From COVID-19 Vaccine Sues Biden Administration
-
Spread & Containment14 hours ago
COVID-19 Testing Resumes In Beijing, Shandong, As Reinfection Cases Surge
-
Uncategorized18 hours ago
How do credit scores work? 2 finance professors explain how lenders choose who gets loans and at what interest rate
-
Government18 hours ago
Work requirements don’t work for domestic violence survivors – but Michigan data shows they rarely get waivers they should receive for cash assistance
-
Uncategorized9 hours ago
Small Bank Insiders Are Buying Shares In Their Companies At A Near Record Pace